Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | voltage-gated potassium channel | 0.0122 | 0.4009 | 0.5225 |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.0112 | 0.3549 | 1 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0105 | 0.3221 | 0.5 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0122 | 0.4009 | 0.5225 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0105 | 0.3221 | 0.5 |
Brugia malayi | hypothetical protein | 0.0043 | 0.0488 | 0.1376 |
Loa Loa (eye worm) | hypothetical protein | 0.0257 | 1 | 1 |
Echinococcus multilocularis | geminin | 0.0205 | 0.7672 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.7672 | 1 |
Loa Loa (eye worm) | inward rectifying k channel family protein 1 | 0.0257 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.0488 | 0.5 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0112 | 0.3549 | 0.4627 |
Loa Loa (eye worm) | hypothetical protein | 0.0257 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.0488 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.0488 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.0257 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.0488 | 0.0637 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.0488 | 0.0637 |
Echinococcus granulosus | geminin | 0.0205 | 0.7672 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0097 | 0.289 | 0.289 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.7672 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.0488 | 0.5 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0112 | 0.3549 | 0.4627 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0112 | 0.3549 | 0.3549 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.0488 | 0.0637 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.0488 | 0.0637 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.8199 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 12.9953 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.